Gilead Sciences press release
FOSTER CITY, Calif., February 17, 2026 — Gilead Sciences, Inc. today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado.
– Pivotal Phase 3 findings support the potential of a novel single-tablet combination of bictegravir and lenacapavir for HIV treatment –
– Latest data from the PURPOSE program further demonstrates the safety and efficacy profile of twice-yearly lenacapavir for HIV prevention –
Read the full press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
HIV i-Base: HPV and anal cancer in HIV+ gay men: new campaign in Manchester: anal HPV in gay men on PrEP
-
[Press release] ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
-
WHO: Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.